2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, Zhang J, Awad MM, Leonardi GC, Johnson DB, Pinato DJ, Owen DH, Weiss SA, Lamberti G, Lythgoe MP, Manuzzi L, Arnold C, Qiao W, Naidoo J, Markel G, Powell N, Yeung SJ, Sharon E, Dougan M, Wang Y. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal Of Clinical Oncology 2019, 38: 576-583. PMID: 31800340, PMCID: PMC7030892, DOI: 10.1200/jco.19.01674.Peer-Reviewed Original ResearchConceptsGI adverse eventsInflammatory bowel diseaseImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsAdverse eventsCheckpoint inhibitorsBowel diseaseInhibitor therapyAnti-cytotoxic T-lymphocyte antigen-4 therapyTreatment of IBDCytotoxic T-lymphocyte antigen-4T-lymphocyte antigen-4Cell death 1Multivariate logistic regressionImmunotherapy initiationColonic perforationGI eventsDeath-1Ulcerative colitisCrohn's diseaseMedian timeMultivariable analysisRetrospective studySimilar patients
2014
Update on Vaccines for High-Risk Melanoma
Weiss SA, Chandra S, Pavlick AC. Update on Vaccines for High-Risk Melanoma. Current Treatment Options In Oncology 2014, 15: 269-280. PMID: 24788575, DOI: 10.1007/s11864-014-0283-7.Peer-Reviewed Original ResearchConceptsHigh-risk melanomaRole of vaccinesClinical trialsCytotoxic T-lymphocyte antigen-4Death-1 monoclonal antibodyT-lymphocyte antigen-4Cell death-1 monoclonal antibodyImmunogenic solid tumorsOpinion statementThe managementPrimary surgical resectionHigh-risk diseaseMeaningful clinical responsesGranulocyte-macrophage colony-stimulating factorImmune stimulatory agentsDevelopment of vaccinesMacrophage colony-stimulating factorColony-stimulating factorAdjuvant settingImmunomodulatory therapyAdjuvant optionClinical responseMelanoma vaccineSurgical resectionVaccine therapyClinical outcomes